SENORES PHARMACEUTICALS L
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, ne… Read more
SENORES PHARMACEUTICALS L (SENORES) - Total Liabilities
Latest total liabilities as of September 2025: ₹4.54 Billion INR
Based on the latest financial reports, SENORES PHARMACEUTICALS L (SENORES) has total liabilities worth ₹4.54 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
SENORES PHARMACEUTICALS L - Total Liabilities Trend (2022–2025)
This chart illustrates how SENORES PHARMACEUTICALS L's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
SENORES PHARMACEUTICALS L Competitors by Total Liabilities
The table below lists competitors of SENORES PHARMACEUTICALS L ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Emro Inc.
KQ:058970
|
Korea | ₩22.37 Billion |
|
Inmobiliaria del Sur SA
MC:ISUR
|
Spain | €352.61 Million |
|
Zeng Hsing Industrial Co Ltd
TW:1558
|
Taiwan | NT$4.64 Billion |
|
Duksan Hi Metal Co.Ltd
KQ:077360
|
Korea | ₩353.87 Billion |
|
Flexsteel Industries Inc
NASDAQ:FLXS
|
USA | $111.33 Million |
|
Guangdong Greenway Technology Co Ltd
SHG:688345
|
China | CN¥1.78 Billion |
|
AUPU Home Style Corp Ltd
SHG:603551
|
China | CN¥727.16 Million |
|
Aeluma, Inc
NASDAQ:ALMU
|
USA | $1.77 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down SENORES PHARMACEUTICALS L's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SENORES PHARMACEUTICALS L's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SENORES PHARMACEUTICALS L (2022–2025)
The table below shows the annual total liabilities of SENORES PHARMACEUTICALS L from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹50.70 Million | -98.70% |
| 2024-03-31 | ₹3.90 Billion | +356.05% |
| 2023-03-31 | ₹855.54 Million | +279.20% |
| 2022-03-31 | ₹225.62 Million | -- |